Securities Lawsuits Set October Deadlines for Three Firms
Securities Lawsuits Set October Deadlines for Three Firms
Anonymous
Key Points
1
Aardvark Therapeutics investors face a separate lead-plaintiff deadline of October 13, 2026.
2
The Aardvark notice says investors may explore recovery even if they continue to hold their shares, and participation carries no cost or obligation.
3
The GoDaddy and ARS Pharmaceuticals notices state that class-action lawsuits have already been filed; investors seeking lead-plaintiff status must petition the court by the applicable deadline, with the lead plaintiff serving as the representative directing the litigation.
4
The notices provide contact details for prospective claimants: Rosen Law Firm directs GoDaddy and ARS investors to its online enrollment pages or to contact attorney Phillip Kim, while Levi & Korsinsky directs Aardvark investors to attorney Joseph E. Levi.
Three companies face securities class-action lawsuits with fast-approaching deadlines for investors seeking lead-plaintiff status. Rosen Law Firm and Levi & Korsinsky have announced deadlines ranging from October 5 to October 20, 2026, giving eligible investors a narrow window to join the cases at no cost.
The three firms involved—GoDaddy, Aardvark Therapeutics, and ARS Pharmaceuticals—are accused of various securities violations. Investors who held shares during specific periods can participate without upfront fees, though the allegations remain unproven in court.
GoDaddy and ARS Investors Face October Deadlines
GoDaddy investors who bought shares between September 3, 2025, and February 24, 2026, must seek lead-plaintiff status by October 20, 2026, Rosen Law Firm announced. Rosen is directing eligible investors to an online enrollment page or to contact attorney Phillip Kim directly. Lead plaintiffs serve as representatives who guide the litigation on behalf of all shareholders.
ARS Pharmaceuticals investors face an earlier deadline of October 5, 2026. The window covers shares purchased between March 9 and June 24, 2026. Rosen Law Firm handles this case too and encourages interested parties to act quickly before the cutoff passes.
Aardvark Alleges Misrepresented Drug Safety
Aardvark Therapeutics investors who bought shares in or traceable to the company's February 2025 initial public offering—or between February 13, 2025, and May 14, 2026—can join a separate lawsuit. Levi & Korsinsky is handling this case and set an October 13, 2026, deadline for lead-plaintiff status. The complaint alleges Aardvark misrepresented the safety and prospects of its ARD-101 treatment.
Aardvark investors may pursue recovery even if they still hold their shares. Levi & Korsinsky emphasizes that participation carries no cost or obligation. Attorney Joseph E. Levi is available to answer questions from prospective claimants about their eligibility and options.
How Lead-Plaintiff Status Works
Investors seeking lead-plaintiff status must petition the court before each deadline passes. The lead plaintiff becomes the named representative in court filings and works closely with attorneys to direct settlement negotiations or trial strategy. Unlike individual lawsuits, class actions pool thousands of shareholders into one case, reducing legal costs for all participants.
All three lawsuits are already filed in court. Investors need only petition the court within the deadline window—they do not need to file separately or pay anything upfront. Recovery, if any is awarded, comes from settlement proceeds or judgments, not from investors' pockets.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
25
Articles
151
Reach
176
A
AnonymousAuthor
